Loading clinical trials...
Loading clinical trials...
The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.
Prospective study of patients seen at the Univ. of Chicago Medical Center hospital and ambulatory clinics. The assessment of the MAsS score will require an additional 8-10 minutes in the MRI for each patient already undergoing MRI exam. Four groups of pts. who are already scheduled for MRI for routine clinical purposes will be evaluated. 1. Pts. hospitalized with acute hepatic decompensation for whom MRI is otherwise indicated for clinical evaluation. 2. Pts. with hepatobiliary neoplasia 3. Pts.undergoing transjugular portosystemic shunt (TIPS) placement 4. Pts. with chronic liver disease undergoing magnetic resonance elastography for routine monitoring
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
The University of Chicago
Chicago, Illinois, United States
Start Date
April 18, 2022
Primary Completion Date
March 1, 2027
Completion Date
March 1, 2027
Last Updated
January 14, 2026
1,200
ESTIMATED participants
Lead Sponsor
University of Chicago
NCT06493773
NCT07150624
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions